Patents Assigned to ABL BIO INC.
-
Patent number: 11891445Abstract: Provided is an anti-B7-H3 antibody specifically recognizing a B7-H3, which can be usefully as a cancer therapeutic agent, as having an inhibitory activity of an immune checkpoint which induces antibody-dependent cell-mediated cytotoxicity and T cell activation inhibited by B7-H3. In particular, the antibody having the inhibitory activity of an immune checkpoint can be used in combination with other immunoantibody therapeutic agents. In addition, it can be usefully used for cancer targeting treatment including detection of various cancers expressing B7-H3 through specific binding to B7-H3, and drug delivery to specific cancer, etc.Type: GrantFiled: May 24, 2019Date of Patent: February 6, 2024Assignee: ABL BIO INC.Inventors: Kyeongsu Park, Yangsoon Lee, Hyejin Chung, Uijung Jung, Yong-Gyu Son, Sang-Jun Ha, Myeong Joon Kim, Eunyoung Park, Kyungjin Park, Eunsil Sung, Yeunju Kim, Jinhyung Ahn, Byungje Sung, Daehae Song, Youngdon Pak
-
Publication number: 20230357412Abstract: The present disclosure relates to a bispecific antibody that specifically binds to alpha-synuclein and IGF1R, and an use of the bispecific antibody for the prevention, treatment and / or diagnosis of synucleinopatheis associated with alpha-synuclein or alpha-synuclein aggregates, and can allow the alpha-synuclein antibody or an antigen-binding fragment thereof to penetrate the blood brain barrier to exert its action in the brain, and extend the half-life to maintain the efficacy for a long time.Type: ApplicationFiled: December 8, 2022Publication date: November 9, 2023Applicant: ABL BIO INC.Inventors: Sungwon AN, Jinhyung AHN, Byungje SUNG, Dongin KIM, Daehae SONG, Jaehyun EOM, Yong-Gyu SON, Juhee KIM, Kyungjin PARK, Jinwon JUNG, Bora LEE, Hyesu YUN
-
Patent number: 11707533Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.Type: GrantFiled: July 27, 2020Date of Patent: July 25, 2023Assignees: LegoChem Biosciences, Inc., ABL Bio, Inc.Inventors: Yun-Hee Park, Ho Young Song, Hyun Min Ryu, Sung Min Kim, Ju Yuel Baek, Ji Hye Oh, Nara Han, Hyoung Rae Kim, Kyung Eun Park, Hyeun Joung Lee, Ju Young Lee, Dae Hyuck Kang, Young-Jae Yang, Ji-Na You, Yong Zu Kim, Chang Sun Lee, Jeiwook Chae, Jinwon Jung, Juhee Kim, Bora Lee, Daehae Song, Byungje Sung, Donghoon Yeom, Jaehyun Eom, Youngeun Hong, Jinhyung Ahn, Yangsoon Lee, Kyungjin Park, Jiseon Yoo, Minji Park
-
Publication number: 20230212217Abstract: Provided is a method of purifying a mixture of Fc-containing bioactive peptides by using an affinity column including an affinity matrix containing a protein A ligand, wherein the mixture of Fc-containing bioactive peptides includes a first Fc-containing bioactive peptide and a second Fc-containing bioactive peptide, and the second Fc-containing bioactive peptide includes at least one more human VH3 domain, compared to the first Fc-containing bioactive peptide. According to the purification method, bioactive peptides having the same or similar structures can be precisely separated to the high level of purity while simplification of the process is achieved.Type: ApplicationFiled: December 24, 2020Publication date: July 6, 2023Applicant: ABL BIO INC.Inventors: Daehae Song, Youngdon Pak, Jinwon Jung, Junghyeon Hong, Heejin Lim, Dongin Kim
-
Publication number: 20220363763Abstract: The present disclosure provides an anti-PD-L1/anti-LAG3 bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between LAG3 and its ligand (e.g., a MHC class II molecule and FGL1). The bispecific antibody may have high binding affinity to both of a PD-L1 protein (e.g., a human PD-L1 protein) and a LAG3 protein (e.g., a human LAG3 protein). Also provided are antibodies and fragments that have specificity to the PD-L1 or LAG3 protein alone, or antibodies and fragments having additional specificity to one or more other antigens.Type: ApplicationFiled: August 21, 2019Publication date: November 17, 2022Applicant: ABL BIO INC.Inventors: Eunyoung PARK, Yangsoon LEE, Uijung JUNG, YoungKwang KIM, Yeun Ju KIM, Youngdon PAK, Sang Hoon LEE, Weon-Kyoo YOU, Jaeho JUNG, Lei FANG, Wenqing JIANG
-
Patent number: 11261259Abstract: Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.Type: GrantFiled: August 12, 2020Date of Patent: March 1, 2022Assignees: I-Mab Biopharma US Limited, ABL Bio Inc.Inventors: Wenqing Jiang, Lei Fang, Zhengyi Wang, Bingshi Guo, Eunyoung Park, Eunsil Sung, Byungje Sung
-
Publication number: 20220056136Abstract: The present disclosure provides an anti-PD-L1/anti-4-1BB bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between 4-1BB and its ligand. The bispecific antibody may have high binding affinity to both of a PD-L1 protein and a 4-1BB protein.Type: ApplicationFiled: February 15, 2019Publication date: February 24, 2022Applicants: ABL BIO INC., I-MAB BIOPHARMA CO., LTDInventors: Eunyoung PARK, Yangsoon LEE, Hyejin CHUNG, Eunsil SUNG, Jiseon YOO, Minji PARK, Yong-Gyu SON, Hyoju CHOI, Eunjung KIM, Jaeho JUNG, Weon-Kyoo YOU, Sang Hoon LEE, Lei FANG, Wenqing JIANG